EDAP TMS S.A. (EDAP)

[BioSpecialist]

THIS STOCK IS FLYING UNDER RADAR . FDA APPROVAL WILL PUSH THIS STOCK TO 5-7 US$ EASILY . FANTASTIC BUYING OPPORTUNITY AT CURRENT LEVELS !

EDAP is another Hot Cancer Play Like BSDM .


Edap Tms ( NASDAQ: EDAP )

Market Cap : 24 Million$
Cash : 15,8 Million$
Price : 2,20 $

Shares Out : 11,1 M <<< LOW FLOAT


EDAP Reports Publication of Long-Term Clinical Results for Largest Cohort of Ablatherm-HIFU Patients

http://finance.yahoo.com/news/EDAP-Reports-Publication-of-pz-523047653.html?x=0&.v=1


EDAP Media Interview Highlights Prostate Cancer
http://finance.yahoo.com/news/EDAP-Media-Interview-pz-896529322.html?x=0&.v=1


Positive News Coverage of EDAP's Ablatherm-HIFU treatment: "Man beats prostate cancer thanks to annual screening"

http://files.shareholder.com/downloads/EDAP/1049042728x0x404371/7BFE7B83-3399-4282-A11F-2084F81989FB/EDAP_NewsCoverage_9.21.10.pdf



EDAP Submits U.S. FDA 510(k) Application for Marketing Clearance for Sonolith i-move

http://finance.yahoo.com/news/EDAP-Submits-US-FDA-510k-pz-3864869273.html?x=0&.v=1

Press Release Source: EDAP TMS SA On Thursday August 19, 2010, 9:15 am EDT

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We are actively moving forward in obtaining approval in major lithotripsy markets for our recently developed, innovative Sonolith i-move lithotripter. Our recent 510(k) application to the FDA is a clear milestone for EDAP's expansion in this field. In addition to our high-range fully integrated Sonolith I-sys lithotripter that received 510(k) marketing clearance a year ago, our compact multi-configurations Sonolith i-move device offers a wide range of urinary stones treatment options to mid-size clinics and hospitals, hence covering all lithotripsy market segments. We look forward to working with the FDA in view of approval of our Sonolith i-move, hence providing U.S. patients and physicians with the most versatile advanced treatment option."



510(k) Status Program

Submitters may request information on their 510(k) review status 90 days after the initial log-in date of the 510(k).




Homepage
http://investor.edap-tms.com/placements.cfm